<p>缅因州波特兰，2025 年 1 月 9 日（GLOBE NEWSWIRE）— <strong>ImmuCell Corporation</strong></p>
<p><strong><img src="https://imageproxy.pbkrs.com/https://s3-symbol-logo.tradingview.com/immucell-corporation.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://s3-symbol-logo.tradingview.com/immucell-corporation.svg"/></strong></p>
<p><strong>ICCC</strong>（“ImmuCell” 或 “公司”），是一家不断发展的动物健康公司，开发、制造和销售经过科学验证的实用产品，以改善奶牛和肉牛的健康和生产力，今天宣布截至 2024 年 12 月 31 日的第四季度和全年初步未经审计的销售结果。</p>
<p>自 2020 年第一季度以来，公司在季度结束后不久就提供初步的未经审计的销售结果。公司预计将继续提供这一及时的初步产品销售报告，直至另行通知。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>初步未经审计的总销售结果：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2024</td>
<td>2023</td>
<td>增加金额</td>
<td>增长百分比</td>
</tr>
<tr>
<td>截至 12 月 31 日的三个月期间</td>
<td>$7.8 百万</td>
<td>$5.1 百万</td>
<td>$2.7 百万</td>
<td>52%</td>
</tr>
<tr>
<td>截至 12 月 31 日的年度</td>
<td>$26.5 百万</td>
<td>$17.5 百万</td>
<td>$9.0 百万</td>
<td>52%</td>
</tr>
</tbody>
</table>
<p>截至 2024 年 12 月 31 日的三个月期间，年化生产产出约为公司估计的年产能约 3000 万美元的 103%。这一生产产出帮助将订单积压从 2024 年 1 月 1 日的约 940 万美元减少至 2025 年 1 月 1 日的约 440 万美元。公司认为，当前的订单积压反映了强劲的需求，因为分销商正在努力补充其缓冲库存，并且终端用户在第一季度的高峰产犊季节之前提前下单。</p>
<p>“我们继续努力获得 FDA 批准以商业化 <strong>Re-Tain</strong>®，” ImmuCell 的总裁兼首席执行官 Michael F. Brigham 评论道。“在 12 月底，我们的合同制造商提交了对其设施检查观察结果的回应。我们在 1 月提交了我们的非行政 NADA，其中包括我们对 CMC 技术部分的第四次提交（回应之前不完整信函中的小型、非复杂问题），以及所有其他信息和产品标签。我们一直在与 FDA 讨论加快审查我们的申请。”</p>
<p><strong>电话会议：</strong></p>
<p>公司计划于 2025 年 2 月 26 日星期三上午 9:00（东部时间）召开电话会议，讨论截至 2024 年 12 月 31 日的季度和年度未经审计的财务结果。感兴趣的各方可以拨打（844）855-9502（免费）或（412）317-5499（国际）在上午 9:00（东部时间）访问电话会议。会议的电话重播将可用至 2025 年 3 月 5 日，拨打（877）344-7529（免费）或（412）317-0088（国际），使用重播访问代码#5555700。鼓励投资者查看公司的企业演示文稿幻灯片，提供公司业务的概述，并可在公司网站的 “投资者” 标签下找到，网址为 www.immucell.com，或向公司请求。更新版本的幻灯片将在 2025 年 2 月 25 日星期二市场收盘后提供。</p>
<p><strong>关于 ImmuCell：</strong></p>
<p>ImmuCell Corporation（<strong>纳斯达克：ICCC</strong>）的宗旨是创造经过科学验证的实用产品，以改善奶牛和肉牛的健康和生产力。ImmuCell 制造和销售 <strong>First Defense</strong>®，为新生奶牛和肉牛提供 <strong>即时免疫</strong>™，并正在开发 <strong>Re-Tain</strong>®，这是一种新型治疗奶牛亚临床乳腺炎的产品，无需 FDA 要求的牛奶丢弃或肉类保留标签限制，为传统抗生素提供替代方案。有关公司的新闻稿和其他信息可在：http://www.immucell.com 获取。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>联系人：</td>
<td>Michael F. Brigham，总裁兼首席执行官</td>
</tr>
<tr>
<td></td>
<td>ImmuCell Corporation</td>
</tr>
<tr>
<td></td>
<td>(207) 878-2770</td>
</tr>
<tr>
<td></td>
<td>Joe Diaz, Robert Blum 和 Joe Dorame</td>
</tr>
<tr>
<td></td>
<td>Lytham Partners, LLC</td>
</tr>
<tr>
<td></td>
<td>(602) 889-9700</td>
</tr>
<tr>
<td></td>
<td>iccc@lythampartners.com</td>
</tr>
</tbody>
</table>
<p>关于前瞻性声明的警示说明（安全 <strong>港</strong> 声明）：</p>
<p>本新闻稿及相关电话会议中将要发表的声明包含 1995 年《私人证券诉讼改革法案》及其修正案所定义的 “前瞻性声明”。前瞻性声明的特征在于它们并不严格与历史或当前事实相关，通常会包含诸如 “预计”、“可能”、“预期”、“旨在”、“打算”、“将”、“可以”、“应该”、“会”、“计划”、“相信”、“估计”、“目标”、“项目”、“预测”、“寻求” 等类似词汇和表达。这些声明包括但不限于与以下内容相关的任何前瞻性声明：我们业务的计划和战略；未来财务或运营表现的预测；待处理或预期的监管批准申请的时间和结果；我们产品的未来需求；正在进行和未来产品开发工作的范围和时间以及我们产品的商业化；产品开发工作的未来成本；新产品的预期有效性；关于我们产品市场规模的估计；当前产品和仍在开发中的产品的未来市场份额和收入；我们增加生产产出和降低每单位销售成本的能力；我们自身制造设施或与我们有合同关系的第三方制造设施在及时满足我们产品需求方面的充足性；未来污染事件的可能性、严重性或影响；我们制造过程的稳健性及相关技术问题；关于我们的生产能力、效率和产量的估计；目前在等待 FDA 批准的库存产品的可销售性；与我们产品相关的未来监管要求；未来费用比率和利润率；我们在业务投资中的有效性；我们制造能力和效率的预期变化；我们在现有和预期产品市场中与竞争对手竞争的有效性；我们将订单积压转化为销售的能力；以及任何其他非历史事实的声明。这些声明旨在提供管理层截至本新闻稿日期对未来事件的当前预期，基于管理层截至本日期的估计、预测、信念和假设；并不保证未来的表现。这些声明涉及已知和未知的风险和不确定性，可能导致公司的实际结果、财务或运营表现或成就与这些前瞻性声明所表达或暗示的结果有重大差异，包括但不限于与以下内容相关的风险和不确定性：我们产品（包括 <strong>First Defense</strong> <strong>®</strong> 产品线和 <strong>Re-Tain</strong> <strong>®</strong>）的开发、测试、监管批准、生产和营销中的困难或延误；我们预期产品市场中的竞争；客户对我们新产品和现有产品的接受度；产品性能；我们制造资源与产品需求之间的协调（包括积压的后果）；随着我们走出长期积压，客户订单的时间和数量的不确定性；供应链中断对我们运营及客户和供应商关系的不利影响；与我们当前和计划的生产能力扩张相关的商业和运营风险；以及我们不时向证券交易委员会（SEC）提交的文件中详细说明的其他风险和不确定性，包括我们的 10-Q 表季度报告、10-K 表年度报告和 8-K 表当前报告。这些声明涉及风险和不确定性，基于我们当前的预期，但实际结果可能因各种因素而有重大差异。此外，不能保证影响我们的未来风险、不确定性或发展将是我们所预期的。我们不承担更新任何前瞻性声明的义务，无论是书面还是口头，无论是由于新信息、未来发展还是其他原因。</p>

ICCC

<p>ImmuCell Corporation 宣布了 2024 年第四季度和全年的初步未经审计的销售结果，报告第四季度销售额增长 52%，达到 780 万美元，全年销售额为 2650 万美元。公司已将订单积压减少至 440 万美元，反映出强劲的需求。首席执行官 Michael F. Brigham 强调了为 Re-Tain® 获得 FDA 批准的持续努力。计划于 2025 年 2 月 26 日召开电话会议，讨论财务结果。ImmuCell 专注于提升奶牛和肉牛健康与生产力的产品</p>

<p>PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) — <strong>ImmuCell Corporation</strong></p>
<div class="lb-trans"><p>缅因州波特兰，2025 年 1 月 9 日（GLOBE NEWSWIRE）— <strong>ImmuCell Corporation</strong></p>
</div><p><strong><img src="https://imageproxy.pbkrs.com/https://s3-symbol-logo.tradingview.com/immucell-corporation.svg" alt="" original-src="https://s3-symbol-logo.tradingview.com/immucell-corporation.svg"/></strong></p>
<div class="lb-trans"><p><strong><img src="https://imageproxy.pbkrs.com/https://s3-symbol-logo.tradingview.com/immucell-corporation.svg" alt="" original-src="https://s3-symbol-logo.tradingview.com/immucell-corporation.svg"/></strong></p>
</div><p><strong>ICCC</strong>(“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2024.</p>
<div class="lb-trans"><p><strong>ICCC</strong>（“ImmuCell” 或 “公司”），是一家不断发展的动物健康公司，开发、制造和销售经过科学验证的实用产品，以改善奶牛和肉牛的健康和生产力，今天宣布截至 2024 年 12 月 31 日的第四季度和全年初步未经审计的销售结果。</p>
</div><p>Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.</p>
<div class="lb-trans"><p>自 2020 年第一季度以来，公司在季度结束后不久就提供初步的未经审计的销售结果。公司预计将继续提供这一及时的初步产品销售报告，直至另行通知。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Preliminary, Unaudited Total Sales Results:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2024</td>
<td>2023</td>
<td>$ Increase</td>
<td>% Increase</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended December 31,</td>
<td>$7.8 million</td>
<td>$5.1 million</td>
<td>$2.7 million</td>
<td>52%</td>
</tr>
<tr>
<td>During the Years Ended December 31,</td>
<td>$26.5 million</td>
<td>$17.5 million</td>
<td>$9.0 million</td>
<td>52%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>初步未经审计的总销售结果：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2024</td>
<td>2023</td>
<td>增加金额</td>
<td>增长百分比</td>
</tr>
<tr>
<td>截至 12 月 31 日的三个月期间</td>
<td>$7.8 百万</td>
<td>$5.1 百万</td>
<td>$2.7 百万</td>
<td>52%</td>
</tr>
<tr>
<td>截至 12 月 31 日的年度</td>
<td>$26.5 百万</td>
<td>$17.5 百万</td>
<td>$9.0 百万</td>
<td>52%</td>
</tr>
</tbody>
</table>
</div><p>During the three-month period ended December 31, 2024, annualized production output was approximately 103% of the Company’s estimated full capacity of approximately $30 million per year. This production output helped reduce the backlog of orders to approximately $4.4 million as of January 1, 2025 from approximately $9.4 million as of January 1, 2024. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of peak calving season during the first quarter.</p>
<div class="lb-trans"><p>截至 2024 年 12 月 31 日的三个月期间，年化生产产出约为公司估计的年产能约 3000 万美元的 103%。这一生产产出帮助将订单积压从 2024 年 1 月 1 日的约 940 万美元减少至 2025 年 1 月 1 日的约 440 万美元。公司认为，当前的订单积压反映了强劲的需求，因为分销商正在努力补充其缓冲库存，并且终端用户在第一季度的高峰产犊季节之前提前下单。</p>
</div><p>“We continue to work to achieve FDA approval to commercialize <strong>Re-Tain</strong> ®,” commented Michael F. Brigham, President and CEO of ImmuCell. “In late December, our contract manufacturer submitted its response to inspectional observations pertaining to its facilities. We just filed our Non-Administrative NADA in January, which included our fourth submission of the CMC Technical Section (responding to the minor, non-complex issues from the prior Incomplete Letter) together with All Other Information and Product Labeling. We have been in discussions with the FDA about an expedited review of our filing.”</p>
<div class="lb-trans"><p>“我们继续努力获得 FDA 批准以商业化 <strong>Re-Tain</strong>®，” ImmuCell 的总裁兼首席执行官 Michael F. Brigham 评论道。“在 12 月底，我们的合同制造商提交了对其设施检查观察结果的回应。我们在 1 月提交了我们的非行政 NADA，其中包括我们对 CMC 技术部分的第四次提交（回应之前不完整信函中的小型、非复杂问题），以及所有其他信息和产品标签。我们一直在与 FDA 讨论加快审查我们的申请。”</p>
</div><p><strong>Conference Call:</strong></p>
<div class="lb-trans"><p><strong>电话会议：</strong></p>
</div><p>The Company is planning to host a conference call on Wednesday, February 26, 2025 at 9:00 AM ET to discuss the unaudited financial results for the quarter and year ended December 31, 2024. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until March 5, 2025 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #5555700. Investors are encouraged to review the Company’s Corporate Presentation slide deck that provides an overview of the Company’s business and is available under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company. An updated version of the slide deck will be made available after the market closes on Tuesday, February 25, 2025.</p>
<div class="lb-trans"><p>公司计划于 2025 年 2 月 26 日星期三上午 9:00（东部时间）召开电话会议，讨论截至 2024 年 12 月 31 日的季度和年度未经审计的财务结果。感兴趣的各方可以拨打（844）855-9502（免费）或（412）317-5499（国际）在上午 9:00（东部时间）访问电话会议。会议的电话重播将可用至 2025 年 3 月 5 日，拨打（877）344-7529（免费）或（412）317-0088（国际），使用重播访问代码#5555700。鼓励投资者查看公司的企业演示文稿幻灯片，提供公司业务的概述，并可在公司网站的 “投资者” 标签下找到，网址为 www.immucell.com，或向公司请求。更新版本的幻灯片将在 2025 年 2 月 25 日星期二市场收盘后提供。</p>
</div><p><strong>About ImmuCell:</strong></p>
<div class="lb-trans"><p><strong>关于 ImmuCell：</strong></p>
</div><p>ImmuCell Corporation's ( <strong>Nasdaq: ICCC</strong>) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets <strong>First Defense</strong> ®, providing <strong>Immediate Immunity</strong> ™ to newborn dairy and beef calves, and is in the late stages of developing <strong>Re-Tain</strong> <strong>®</strong>, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or meat withhold label restrictions that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.</p>
<div class="lb-trans"><p>ImmuCell Corporation（<strong>纳斯达克：ICCC</strong>）的宗旨是创造经过科学验证的实用产品，以改善奶牛和肉牛的健康和生产力。ImmuCell 制造和销售 <strong>First Defense</strong>®，为新生奶牛和肉牛提供 <strong>即时免疫</strong>™，并正在开发 <strong>Re-Tain</strong>®，这是一种新型治疗奶牛亚临床乳腺炎的产品，无需 FDA 要求的牛奶丢弃或肉类保留标签限制，为传统抗生素提供替代方案。有关公司的新闻稿和其他信息可在：http://www.immucell.com 获取。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Contacts:</td>
<td>Michael F. Brigham, President and CEO</td>
</tr>
<tr>
<td></td>
<td>ImmuCell Corporation</td>
</tr>
<tr>
<td></td>
<td>(207) 878-2770</td>
</tr>
<tr>
<td></td>
<td>Joe Diaz, Robert Blum and Joe Dorame</td>
</tr>
<tr>
<td></td>
<td>Lytham Partners, LLC</td>
</tr>
<tr>
<td></td>
<td>(602) 889-9700</td>
</tr>
<tr>
<td></td>
<td>iccc@lythampartners.com</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>联系人：</td>
<td>Michael F. Brigham，总裁兼首席执行官</td>
</tr>
<tr>
<td></td>
<td>ImmuCell Corporation</td>
</tr>
<tr>
<td></td>
<td>(207) 878-2770</td>
</tr>
<tr>
<td></td>
<td>Joe Diaz, Robert Blum 和 Joe Dorame</td>
</tr>
<tr>
<td></td>
<td>Lytham Partners, LLC</td>
</tr>
<tr>
<td></td>
<td>(602) 889-9700</td>
</tr>
<tr>
<td></td>
<td>iccc@lythampartners.com</td>
</tr>
</tbody>
</table>
</div><p>Cautionary Note Regarding Forward-Looking Statements (Safe <strong>Harbor</strong> <strong>Statement):</strong></p>
<div class="lb-trans"><p>关于前瞻性声明的警示说明（安全 <strong>港</strong> 声明）：</p>
</div><p>This Press Release and the statements to be made in the related conference call referenced herein contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans and strategies for our business; projections of future financial or operational performance; the timing and outcome of pending or anticipated applications for regulatory approvals; future demand for our products; the scope and timing of ongoing and future product development work and commercialization of our products; future costs of product development efforts; the expected efficacy of new products; estimates about the market size for our products; future market share of and revenue generated by current products and products still in development; our ability to increase production output and reduce costs of goods sold per unit; the adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the likelihood, severity or impact of future contamination events; the robustness of our manufacturing processes and related technical issues; estimates about our production capacity, efficiency and yield; the salability of products currently held in inventory pending FDA approval; future regulatory requirements relating to our products; future expense ratios and margins; the effectiveness of our investments in our business; anticipated changes in our manufacturing capabilities and efficiencies; our effectiveness in competing against competitors within both our existing and our anticipated product markets; our ability to convert the backlog of orders into sales; and any other statements that are not historical facts. These statements are intended to provide management's current expectation of future events as of the date of this press release, are based on management's estimates, projections, beliefs and assumptions as of the date hereof; and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties relating to: difficulties or delays in development, testing, regulatory approval, production and marketing of our products (including the <strong>First Defense</strong> <strong>®</strong> product line and <strong>Re-Tain</strong> <strong>®</strong>), competition within our anticipated product markets, customer acceptance of our new and existing products, product performance, alignment between our manufacturing resources and product demand (including the consequences of backlogs), uncertainty associated with the timing and volume of customer orders as we come out of a prolonged backlog, adverse impacts of supply chain disruptions on our operations and customer and supplier relationships, commercial and operational risks relating to our current and planned expansion of production capacity, and other risks and uncertainties detailed from time to time in filings we make with the Securities and Exchange Commission (SEC), including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to various factors. In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p>
<div class="lb-trans"><p>本新闻稿及相关电话会议中将要发表的声明包含 1995 年《私人证券诉讼改革法案》及其修正案所定义的 “前瞻性声明”。前瞻性声明的特征在于它们并不严格与历史或当前事实相关，通常会包含诸如 “预计”、“可能”、“预期”、“旨在”、“打算”、“将”、“可以”、“应该”、“会”、“计划”、“相信”、“估计”、“目标”、“项目”、“预测”、“寻求” 等类似词汇和表达。这些声明包括但不限于与以下内容相关的任何前瞻性声明：我们业务的计划和战略；未来财务或运营表现的预测；待处理或预期的监管批准申请的时间和结果；我们产品的未来需求；正在进行和未来产品开发工作的范围和时间以及我们产品的商业化；产品开发工作的未来成本；新产品的预期有效性；关于我们产品市场规模的估计；当前产品和仍在开发中的产品的未来市场份额和收入；我们增加生产产出和降低每单位销售成本的能力；我们自身制造设施或与我们有合同关系的第三方制造设施在及时满足我们产品需求方面的充足性；未来污染事件的可能性、严重性或影响；我们制造过程的稳健性及相关技术问题；关于我们的生产能力、效率和产量的估计；目前在等待 FDA 批准的库存产品的可销售性；与我们产品相关的未来监管要求；未来费用比率和利润率；我们在业务投资中的有效性；我们制造能力和效率的预期变化；我们在现有和预期产品市场中与竞争对手竞争的有效性；我们将订单积压转化为销售的能力；以及任何其他非历史事实的声明。这些声明旨在提供管理层截至本新闻稿日期对未来事件的当前预期，基于管理层截至本日期的估计、预测、信念和假设；并不保证未来的表现。这些声明涉及已知和未知的风险和不确定性，可能导致公司的实际结果、财务或运营表现或成就与这些前瞻性声明所表达或暗示的结果有重大差异，包括但不限于与以下内容相关的风险和不确定性：我们产品（包括 <strong>First Defense</strong> <strong>®</strong> 产品线和 <strong>Re-Tain</strong> <strong>®</strong>）的开发、测试、监管批准、生产和营销中的困难或延误；我们预期产品市场中的竞争；客户对我们新产品和现有产品的接受度；产品性能；我们制造资源与产品需求之间的协调（包括积压的后果）；随着我们走出长期积压，客户订单的时间和数量的不确定性；供应链中断对我们运营及客户和供应商关系的不利影响；与我们当前和计划的生产能力扩张相关的商业和运营风险；以及我们不时向证券交易委员会（SEC）提交的文件中详细说明的其他风险和不确定性，包括我们的 10-Q 表季度报告、10-K 表年度报告和 8-K 表当前报告。这些声明涉及风险和不确定性，基于我们当前的预期，但实际结果可能因各种因素而有重大差异。此外，不能保证影响我们的未来风险、不确定性或发展将是我们所预期的。我们不承担更新任何前瞻性声明的义务，无论是书面还是口头，无论是由于新信息、未来发展还是其他原因。</p>
</div>

ImmuCell 宣布 2024 年第四季度和全年的初步未经审计的销售结果